Pharming Group (CH:PHGN)
:PHGN
PHGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow materially improves funding flexibility for launches, R&D and commercialization without immediate financing. Over the next 2–6 months this durable cash generation reduces refinancing risk and supports execution of pipeline and prelaunch spending.
Improving Balance Sheet LeverageLower and improving leverage enhances financial resilience and gives the company room to invest in growth or absorb shocks. This structural de‑risking supports sustained R&D and launch programs and reduces vulnerability to interest rate or liquidity shocks in the medium term.
Joenja Regulatory & Geographic ProgressRegulatory approvals and planned international launches create a durable pathway to scale Joenja beyond a small base. Successful pediatric approval and market rollouts materially expand the addressable APDS patient pool and diversify revenue away from RUCONEST over the coming months and beyond.
Bears Say
RUCONEST Revenue DeclineRUCONEST remains a core revenue driver; sustained declines driven by channel inventory normalization and planned ex‑U.S. exits can structurally reduce near‑term cash flow. Even with expected H2 recovery, prolonged volume pressure would weaken revenue stability and free cash flow resilience.
Rising Competition In HAE MarketThe emergence of oral competitors and prophylactics changes treatment patterns and can permanently alter RUCONEST utilization. Even if current retention is solid, durable market share erosion or changing prescribing behaviors could shrink RUCONEST’s long‑term revenue base and pricing leverage.
Regulatory Timing Uncertainty For JoenjaA partial resubmission strategy and remaining questions on lower‑dose filing create timeline and outcome uncertainty for a key label expansion. Delays or incomplete approvals would defer meaningful Joenja scale and leave diversification plans exposed in the medium term.
Pharming Group News
PHGN FAQ
What was Pharming Group’s price range in the past 12 months?
Currently, no data Available
What is Pharming Group’s market cap?
Pharming Group’s market cap is CHF714.27M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Jul 30, 2026 which is in 47 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on May 07, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.005.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 706,252,300 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of -$0.005 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in CH:PHGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
PHGN Company Deck
PHGN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced short-term headwinds (an expected RUCONEST revenue decline driven by inventory normalization, ex-U.S. exits and early competitive impacts; a near-term Q2 revenue risk; and some cash/one-time lease impacts) with several substantial positives: strong 34% YoY growth in Joenja, continued patient and prescriber additions for RUCONEST, successful regulatory progress (pediatric resubmission, CHMP positive opinion), upcoming Phase II readouts and napazimone enrollment completion, positive operating cash flow, and continued cost discipline. Management reaffirmed full-year guidance and emphasized pipeline catalysts and durable cash generation, indicating confidence in a return to growth in H2 2026 and beyond.View all CH:PHGN earnings summariesOptions Prices
Currently, No data available
---